Immuron Ltd
IMRN · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D52gen composite 39pct→62; net + operating loss
Notable findings
- No interest coverageInterest coverage -731.63 (cannot cover interest)
- Material weaknessIf we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover any material weaknesses or other deficiencies i
- Net lossNet loss (net margin -71.6%)
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
Key metrics
Gross margin
65.4%
Operating margin
-73.3%
Net margin
-71.6%
Return on equity
-64.6%
Return on assets
-51.5%
ROIC
-52.3%
Revenue growth (QoQ)
46.3%
Interest coverage
-731.6×
Current ratio
5.1×
Tangible book value
$5M
Cash & investments
$2M
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05933525 ↗ | Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model. Diarrhea, Travelers Diarrhea | PHASE2 | Completed | 2024-07-01 |
| NCT03065374 ↗ | Treatment for Clostridium-difficile Infection With IMM529 Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence | PHASE1/PHASE2 | Terminated | 2019-11-07 |
| NCT03042767 ↗ | Anti-LPS Antibody Treatment for Pediatric NAFLD Nonalcoholic Fatty Liver Disease (NAFLD) | PHASE2 | Completed | 2019-10-23 |
| NCT01968382 ↗ | Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis Hepatitis, Alcoholic | PHASE2 | Completed | 2018-12-22 |
| NCT02316717 ↗ | A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis (NASH) | PHASE2 | Completed | 2017-10-30 |
| NCT01466894 ↗ | Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis Nonalcoholic Steatohepatitis | PHASE2 | Withdrawn | 2013-12-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-09-25 | 2025-06-30 | 0001213900-25-091414 ↗ |
| 20-F | 2024-10-01 | 2024-06-30 | 0001213900-24-083654 ↗ |
| 20-F | 2023-09-28 | 2023-06-30 | 0001213900-23-080084 ↗ |
| 20-F | 2022-09-09 | 2022-06-30 | 0001213900-22-054904 ↗ |
| 20-F | 2021-10-29 | 2021-06-30 | 0001213900-21-055241 ↗ |
| 20-F | 2020-10-28 | 2020-06-30 | 0001213900-20-033685 ↗ |
| 20-F | 2019-10-28 | 2019-06-30 | 0001213900-19-021197 ↗ |
| 20-F | 2018-10-31 | 2018-06-30 | 0001615774-18-011717 ↗ |
| 20-F | 2017-11-02 | 2017-06-30 | 0001615774-17-006156 ↗ |